Nestle reports 84% holding in Aimmune Therapeutics
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. (SPN), a Nestle(OTCPK:NSRGY)subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics'(NASDAQ:AIMT)common stock for $34.50/share. The offer expired on October 9.
雀巢(OTCPK：NSRGY)子公司法國興業銀行(Sociétédes Produits NestléS.A.)宣佈要約結果，將購買雀巢的全部流通股免疫治療學(納斯達克股票代碼：AIMT)普通股價格為每股34.50美元。該報價已於10月9日到期。
Equinity Trust Company, the depositary for the offer, has advised Nestlé that, 43,435,583 shares were validly tendered and not withdrawn, which represents, ~84% of the outstanding shares as of the Expiration Date.
此次要約的託管人Equity Trust Company已通知雀巢，43,435,583股股票已被有效投標，未被撤回，這相當於截至到期日流通股的約84%。
See below overview of Nestle business over past 150 years:
以下是雀巢在過去150年的業務概況：
Previously: Nestle to buy Aimmune Therapeutics for $2.6B (Aug. 31)
前情：雀巢將以26億美元收購AImmune Treeutics(8月31日)
Click to subscribe to real-time analytics on NSRGY
單擊以訂閲NSRGY上的實時分析
Now read:Merger Arbitrage Analysis And Spread Performance - October 11, 2020 »
現在請閲讀：合併套利分析和價差表現-2020年10月11日»